Efficacy of a negative conversion trial and subsequent living donor kidney transplant outcome in recipients with a positive lymphocyte crossmatch

Kyu Ha Huh, Soon Il Kim, Dong Jin Joo, Man Ki Ju, Hye Kyung Chang, Hae Jin Kim, Yu Seun Kim, Myoung Soo Kim

Research output: Contribution to journalArticle

4 Citations (Scopus)


Background: Patients with a positive lymphocyte crossmatch (LCX) do not undergo kidney transplantation. In such patients, a negative conversion protocol consisting of intravenous immunoglobulin (IVIG), plasmapheresis, and potent immunosuppressant is one of the options for transplantation. Methods: 14 patients who showed a positive LCX with living donors underwent a trial of negative conversion between January 2002 and July 2007. Plasmapheresis was performed every other day, up to 6 times maximum. IVIG was infused after plasmapheresis, with a total dose of 500 mg/kg divided over 6 days. Kidney transplantation was performed immediately after negative conversion. Anti-thymocyte globulin (ATG) or OKT3 induction therapy was used with the combination of tacrolimus, mycophenolate mofetil, and prednisone in the perioperative period. Results: Negative conversion of LCX was achieved in 13 of 14 patients (92.9%). Transplantations were performed successfully in these 13 patients without hyperacute rejection. Four recipients developed acute rejection, which was well controlled by steroid pulse therapy. During the follow-up periods of 45.4 ± 22.0 months, all recipients except 1 showed excellent graft function. Conclusion: Selected patients with a positive LCX can undergo successful transplantation using plasmapheresis, IVIG, and potent immunosuppressants. Recipients with negative conversion of LCX showed acceptable posttransplant results.

Original languageEnglish
Pages (from-to)c49-c54
JournalNephron - Clinical Practice
Issue number1
Publication statusPublished - 2009 Jan 1


All Science Journal Classification (ASJC) codes

  • Nephrology

Cite this